샘플 요청 목록

 카트 문의
시장보고서
상품코드
1751200

감염증 체외진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 검사 위치별, 지역별, 부문별 예측(2025-2030년)

Infectious Disease In Vitro Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Software), By Technology, By Application, By Test Location, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 190 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

감염증 체외진단 시장 성장과 동향:

그랜드 뷰 리서치(Grand View Research, Inc.)의 최신 보고서에 따르면, 세계 감염증 체외진단 시장 규모는 2025년부터 2030년까지 2.54%의 CAGR을 기록하며 2030년까지 280억 5,000만 달러에 달할 것으로 예상됩니다.

결핵, COVID-19와 같은 감염병의 유병률 증가와 기술 발전이 향후 몇 년 동안 제품 수요를 견인할 것으로 예상됩니다. 다제내성 감염증의 증가로 인해 감염증의 조기 진단이 강화되고 있습니다. 예를 들어, 2021년 Microbial Drug Resistance Journal에 따르면 중증 SARS-CoV-2 환자의 MDR 감염 유병률은 14%-50%였습니다.

감염 진단 전 진단과 항생제 치료의 지연은 약제 내성균의 확산을 더욱 가속화하여 업계 성장에 유리한 기회를 창출하고 있습니다. 업계에서는 소비자의 수요를 충족시키기 위해 수많은 제품이 출시되고 있습니다. 예를 들어, 2022년 5월, BD는 미국에서 감염성 질환 자동 진단 플랫폼을 발표했습니다. 이 시스템은 1700개의 검체를 적재할 수 있으며, 검체를 선별할 필요가 없어 오류를 줄일 수 있습니다. 다양한 경쟁사들이 제공하는 제품들은 경쟁사 간의 적대적 관계를 강화하기 위해 전략적인 가격 책정이 이루어지고 있습니다.

그러나 민감도와 신념의 차이로 인해 소비자가 PoC 검사와 실험실 기반 검사 중 하나를 선택해야 하는 경우, 구매 행동의 복잡성은 눈에 띄게 증가합니다. 업계는 과점적이며, 호프만 라 로슈, 아레르, 바이오머티리얼, BD 등이 대부분의 점유율을 차지하고 있습니다. 전 세계 업계는 가격에 민감하고, 비용 효율적이고 효율적인 제품을 생산한다는 점에서 기업들 간에 치열한 경쟁이 벌어지고 있습니다. 신규 바이오마커 키트의 출시가 예상됨에 따라 경쟁사 간의 적대적 관계는 예측 기간 동안 증가할 것으로 보입니다. 경쟁사들은 더 높은 시장 점유율을 확보하기 위해 제품 출시 및 인지도 향상 프로그램 실시와 같은 중요한 전략을 채택하고 있습니다.

감염증 체외진단 시장 보고서 하이라이트

  • 시약 제품 부문은 검사에 대량으로 사용되면서 2024년 가장 큰 매출 점유율을 차지했습니다.
  • 용도별로는 COVID-19 분야가 2024년 업계를 지배했습니다. 이는 바이러스 확산을 억제하기 위해 검사에 대한 지출이 많기 때문입니다.
  • 검사 장소를 기준으로 2024년에는 중앙 검사실 부문이 48.06%의 점유율로 지배적이었습니다. 이는 실험실 기반 검사의 높은 정확도로 인해 PoC 및 가정 내 검사에 비해 신뢰성이 높고, 이러한 검사가 다른 두 부문에 비해 경쟁 우위를 점하고 있기 때문입니다.
  • 북미는 양호한 규제 체계, 예방 및 조기 검사에 대한 집중, 높은 신규 진단약 채택률로 인해 2024년 세계 산업에서 우위를 점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 감염증 체외진단 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 감염증 체외진단 시장 분석 툴
    • Porters 분석
    • PESTEL 분석

제4장 감염증 체외진단 시장 : 제품별 추정·동향 분석

  • 부문 대시보드
  • 감염증 체외진단 시장 : 제품별 변동 분석, 2024년 및 2030년
  • 기기
    • MRSA
    • 연쇄구균
    • 클로스트리듐 디피실
    • VRE
    • CRE
    • 호흡기 바이러스
    • 칸디다
    • 결핵과 약제 내성 결핵
    • 위장 패널 검사
    • 클라미디아
    • 임질
    • HPV
    • HIV
    • C형 간염
    • B형 간염
    • COVID-19
    • 기타 감염증
  • 시약
    • MRSA
    • 연쇄구균
    • 클로스트리듐 디피실
    • VRE
    • CRE
    • 호흡기 바이러스
    • 칸디다
    • 결핵과 약제 내성 결핵
    • 위장 패널 검사
    • 클라미디아
    • 임질
    • HPV
    • HIV
    • C형 간염
    • B형 간염
    • COVID-19
    • 기타 감염증
  • 소프트웨어
    • MRSA
    • 연쇄구균
    • 클로스트리듐 디피실
    • VRE
    • CRE
    • 호흡기 바이러스
    • 칸디다
    • 결핵과 약제 내성 결핵
    • 위장 패널 검사
    • 클라미디아
    • 임질
    • HPV
    • HIV
    • C형 간염
    • B형 간염
    • COVID-19
    • 기타 감염증

제5장 감염증 체외진단 시장 : 기술별 추정·동향 분석

  • 부문 대시보드
  • 감염증 체외진단 시장 : 기술별 변동 분석, 2024년 및 2030년
  • 면역측정
  • 분자진단
    • 중합효소 연쇄 반응(PCR)
    • ISH(In Situ Hybridization)
    • 등온 핵산 증폭 기술(INAAT)
    • 칩과 마이크로어레이
    • 시퀀싱과 NGS
    • 전사 매개 증폭
  • 미생물학
  • 기타

제6장 감염증 체외진단 시장 : 용도별 추정·동향 분석

  • 부문 대시보드
  • 감염증 체외진단 시장 : 용도별 변동 분석, 2024년 및 2030년
  • MRSA
  • 연쇄구균
  • 클로스트리듐 디피실
  • VRE
  • CRE
  • 호흡기 바이러스
  • 칸디다
  • 결핵과 약제 내성 결핵
  • 위장 패널 검사
  • 클라미디아
  • 임질
  • HPV
  • HIV
  • C형 간염
  • B형 간염
  • COVID-19
  • 기타 감염증
    • 기타 시장 매출 추정과 예측, 2018-

제7장 감염증 체외진단 시장 : 검사 위치별 추정·동향 분석

  • 부문 대시보드
  • 감염증 체외진단 시장 : 검사 위치별 변동 분석, 2024년 및 2030년
  • POC(Point of Care)
  • 중앙연구소
  • 기타

제8장 감염증 체외진단 시장 : 지역별 추정·동향 분석

  • 감염증 체외진단 시장 점유율(지역별, 2024년 및 2030년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 스웨덴
    • 덴마크
    • 노르웨이
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 호주
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트
    • 남아프리카공화국
    • 쿠웨이트

제9장 경쟁 구도

  • 주요 시장 진입 기업의 최근 동향과 영향 분석
  • 기업 분류
  • 기업의 시장 점유율 분석
  • 기업 히트맵 분석
  • 전략 매핑
    • 확대
    • 인수합병
    • 파트너십과 협업
    • 신제품 발매
    • 연구개발
  • 기업 개요
    • QIAGEN
    • BD
    • bioMerieux SA
    • F. Hoffmann-La Roche, Ltd.
    • Hologic, Inc.(Gen Probe)
    • Abbott
    • Quidel Corporation
    • Siemens Healthineers AG
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • OraSure Technologies, Inc.
ksm 25.06.26

Infectious Disease In Vitro Diagnostics Market Growth & Trends:

The global infectious disease in vitro diagnostics market size is estimated to reach USD 28.05 billion by 2030, registering a CAGR of 2.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of infectious diseases, such as tuberculosis & COVID-19, and technological advancements are projected to drive the product demand in the coming years. The rising prevalence of multi-drug resistant infections is enhancing the early diagnosis of infectious diseases. For instance, MDR infections are highly common in ICU patients, as per the Microbial Drug Resistance Journal in 2021, the prevalence of MDR infections in critically ill SARS-CoV-2 patients ranged between14% and 50%.

The delay in diagnosis and treatment with antibiotics before infection diagnosis is further escalating the prevalence of drug resistant-bacteria, creating a lucrative opportunity for industry growth. The industry is witnessing a significant number of product launches to meet the demands of consumers. For instance, in May 2022, BD introduced its automated diagnostic platform for infectious diseases in the U.S. The system allows the loading of 1700 specimens and the need for specimen sorting is also eliminated, thereby, reducing errors. Products offered by various competitors have been strategically priced to increase competitive rivalry.

However, complexity in buying behavior increases prominently when consumers have to choose between PoC and lab-based tests owing to differences in sensitivity and beliefs. The industry is oligopolistic with companies, such as Hoffmann-La Roche Ltd., Alere, bioMerieux, and BD, holding the majority of the share collectively. The global industry is price-sensitive, creating rigorous competition among players in terms of manufacturing cost-effective and efficient products. Competitive rivalry is estimated to increase during the forecast period owing to the expected launch of novel biomarker kits. Competitors are adopting key strategies, such as product launches and organizing awareness programs, to gain higher market shares.

Infectious Disease In Vitro Diagnostics Market Report Highlights:

  • The reagents product segment held the largest revenue share in 2024, owing to its high-volume usage in testing.
  • By application, the COVID-19 segment dominated the industry in 2024, due to the high expenditure on testing, to reduce the spread of the virus
  • Based on test location, the central laboratories segment dominated in 2024 with a share of 48.06%, due to the higher accuracy of laboratory-based tests, which makes them more reliable as compared to PoC and home tests, giving these tests a competitive edge over the other two segments
  • North America dominated the global industry in 2024, due to its favorable regulatory framework, focus on preventive & early testing, and the higher adoption rate of novel diagnostics in this region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product
    • 1.2.2. Technology
    • 1.2.3. Application
    • 1.2.4. Test Location
  • 1.3. Regional Scope
  • 1.4. Estimates and Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
  • 1.7. Details of primary research
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity flow analysis (Model 1)
      • 1.9.1.1. Approach 1: Commodity flow approach
    • 1.9.2. Volume price analysis (Model 2)
      • 1.9.2.1. Approach 2: Volume price analysis
  • 1.10. Research Scope and Assumptions
    • 1.10.1. List of Secondary Sources
    • 1.10.2. List of Primary Sources
    • 1.10.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Infectious Disease In Vitro Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Growing geriatric population
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. High demand for PoC facilities
      • 3.2.1.4. Increasing prevalence of infectious diseases
      • 3.2.1.5. External funding for R&D activities
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High prices of IVD tests
  • 3.3. Infectious Disease In Vitro Diagnostics Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Legal landscape

Chapter 4. Infectious Disease In Vitro Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Infectious Disease In Vitro Diagnostics Market: Product Movement Analysis, USD Billion, 2024 & 2030
  • 4.3. Instruments
    • 4.3.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.2. MRSA
      • 4.3.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.3. Streptococcus
      • 4.3.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.4. Clostridium Difficile
      • 4.3.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.5. VRE
      • 4.3.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.6. CRE
      • 4.3.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.7. Respiratory Virus
      • 4.3.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.8. Candida
      • 4.3.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.9. TB and Drug-resistant TB
      • 4.3.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.10. Gastro-intestinal Panel Testing
      • 4.3.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.11. Chlamydia
      • 4.3.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.12. Gonorrhea
      • 4.3.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.13. HPV
      • 4.3.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.14. HIV
      • 4.3.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.15. Hepatitis C
      • 4.3.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.16. Hepatitis B
      • 4.3.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.17. COVID-19
      • 4.3.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.3.18. Other Infectious Diseases
      • 4.3.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Reagents
    • 4.4.1. Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.2. MRSA
      • 4.4.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.3. Streptococcus
      • 4.4.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.4. Clostridium Difficile
      • 4.4.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.5. VRE
      • 4.4.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.6. CRE
      • 4.4.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.7. Respiratory Virus
      • 4.4.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.8. Candida
      • 4.4.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.9. TB and Drug-resistant TB
      • 4.4.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.10. Gastro-intestinal Panel Testing
      • 4.4.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.11. Chlamydia
      • 4.4.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.12. Gonorrhea
      • 4.4.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.13. HPV
      • 4.4.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.14. HIV
      • 4.4.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.15. Hepatitis C
      • 4.4.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.16. Hepatitis B
      • 4.4.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.17. COVID-19
      • 4.4.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.4.18. Other Infectious Diseases
      • 4.4.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Software
    • 4.5.1. Software Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.2. MRSA
      • 4.5.2.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.3. Streptococcus
      • 4.5.3.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.4. Clostridium Difficile
      • 4.5.4.1. Clostridium Difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.5. VRE
      • 4.5.5.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.6. CRE
      • 4.5.6.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.7. Respiratory Virus
      • 4.5.7.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.8. Candida
      • 4.5.8.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.9. TB and Drug-resistant TB
      • 4.5.9.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.10. Gastro-intestinal Panel Testing
      • 4.5.10.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.11. Chlamydia
      • 4.5.11.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.12. Gonorrhea
      • 4.5.12.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.13. HPV
      • 4.5.13.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.14. HIV
      • 4.5.14.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.15. Hepatitis C
      • 4.5.15.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.16. Hepatitis B
      • 4.5.16.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.17. COVID-19
      • 4.5.17.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.5.18. Other Infectious Diseases
      • 4.5.18.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Infectious Disease In Vitro Diagnostics Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Infectious Disease In Vitro Diagnostics Market: Technology Movement Analysis, USD Billion, 2024 & 2030
  • 5.3. Immunoassay
    • 5.3.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Molecular Diagnostics
    • 5.4.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.3. In Situ Hybridization
      • 5.4.3.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
      • 5.4.4.1. Isothermal Nucleic Acid Amplification Technology (INAAT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.5. Chips and Microarrays
      • 5.4.5.1. Chips and Microarrays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.6. Sequencing & NGS
      • 5.4.6.1. Sequencing & NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.4.7. Transcription Mediated Amplification
      • 5.4.7.1. Transcription Mediated Amplification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Microbiology
    • 5.5.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Infectious Disease In Vitro Diagnostics Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Infectious Disease In Vitro Diagnostics Market: Application Movement Analysis, USD Billion, 2024 & 2030
  • 6.3. MRSA
    • 6.3.1. MRSA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Streptococcus
    • 6.4.1. Streptococcus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Clostridium difficile
    • 6.5.1. Clostridium difficile Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. VRE
    • 6.6.1. VRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. CRE
    • 6.7.1. CRE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.8. Respiratory Virus
    • 6.8.1. Respiratory Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.9. Candida
    • 6.9.1. Candida Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.10. TB and drug-resistant TB
    • 6.10.1. TB and Drug-resistant TB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.11. Gastro-intestinal panel testing
    • 6.11.1. Gastro-intestinal Panel Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.12. Chlamydia
    • 6.12.1. Chlamydia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.13. Gonorrhea
    • 6.13.1. Gonorrhea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.14. HPV
    • 6.14.1. HPV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.15. HIV
    • 6.15.1. HIV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.16. Hepatitis C
    • 6.16.1. Hepatitis C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.17. Hepatitis B
    • 6.17.1. Hepatitis B Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.18. COVID-19
    • 6.18.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.19. Other Infectious Diseases
    • 6.19.1. Others Market Revenue Estimates and Forecasts, 2018 -

Chapter 7. Infectious Disease In Vitro Diagnostics Market: Test Location Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Infectious Disease In Vitro Diagnostics Market: Test Location Movement Analysis, USD Billion, 2024 & 2030
  • 7.3. Point of Care
    • 7.3.1. Point of Care Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Central Laboratories
    • 7.4.1. Central Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Infectious Disease In Vitro Diagnostics Market: Regional Estimates & Trend Analysis

  • 8.1. Infectious Disease In Vitro Diagnostics Market Share, By Region, 2024 & 2030, USD Billion
  • 8.2. North America
    • 8.2.1. North America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.2.3. Competitive Insights
      • 8.2.2.4. U.S. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.3.3. Competitive Insights
      • 8.2.3.4. Canada Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.2.4.3. Competitive Insights
      • 8.2.4.4. Mexico Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.2. U.K.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.2.3. Competitive Insights
      • 8.3.2.4. U.K. Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.3.3. Competitive Insights
      • 8.3.3.4. Germany Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.4.3. Competitive Insights
      • 8.3.4.4. France Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.5.3. Competitive Insights
      • 8.3.5.4. Italy Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.6.3. Competitive Insights
      • 8.3.6.4. Spain Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.7.3. Competitive Insights
      • 8.3.7.4. Sweden Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.8. Denmark
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.8.3. Competitive Insights
      • 8.3.8.4. Denmark Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Regulatory Landscape/Reimbursement Scenario
      • 8.3.9.3. Competitive Insights
      • 8.3.9.4. Norway Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.2. China
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. China Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Japan Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. India Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.5.3. Competitive Insights
      • 8.4.5.4. South Korea Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.6.3. Competitive Insights
      • 8.4.6.4. Australia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Regulatory Landscape/Reimbursement Scenario
      • 8.4.7.3. Competitive Insights
      • 8.4.7.4. Thailand Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. Brazil Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Argentina Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Saudi Arabia Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. UAE
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. UAE Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. South Africa
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. South Africa Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Landscape/Reimbursement Scenario
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. Kuwait Infectious Disease In Vitro Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Market Share Analysis
  • 9.4. Company Heat Map Analysis
  • 9.5. Strategy Mapping
    • 9.5.1. Expansion
    • 9.5.2. Mergers & Acquisition
    • 9.5.3. Partnerships & Collaborations
    • 9.5.4. New Product Launches
    • 9.5.5. Research And Development
  • 9.6. Company Profiles
    • 9.6.1. QIAGEN
      • 9.6.1.1. Participant's Overview
      • 9.6.1.2. Financial Performance
      • 9.6.1.3. Product Benchmarking
      • 9.6.1.4. Recent Developments
    • 9.6.2. BD
      • 9.6.2.1. Participant's Overview
      • 9.6.2.2. Financial Performance
      • 9.6.2.3. Product Benchmarking
      • 9.6.2.4. Recent Developments
    • 9.6.3. bioMerieux SA
      • 9.6.3.1. Participant's Overview
      • 9.6.3.2. Financial Performance
      • 9.6.3.3. Product Benchmarking
      • 9.6.3.4. Recent Developments
    • 9.6.4. F. Hoffmann-La Roche, Ltd.
      • 9.6.4.1. Participant's Overview
      • 9.6.4.2. Financial Performance
      • 9.6.4.3. Product Benchmarking
      • 9.6.4.4. Recent Developments
    • 9.6.5. Hologic, Inc. (Gen Probe)
      • 9.6.5.1. Participant's Overview
      • 9.6.5.2. Financial Performance
      • 9.6.5.3. Product Benchmarking
      • 9.6.5.4. Recent Developments
    • 9.6.6. Abbott
      • 9.6.6.1. Participant's Overview
      • 9.6.6.2. Financial Performance
      • 9.6.6.3. Product Benchmarking
      • 9.6.6.4. Recent Developments
    • 9.6.7. Quidel Corporation
      • 9.6.7.1. Participant's Overview
      • 9.6.7.2. Financial Performance
      • 9.6.7.3. Product Benchmarking
      • 9.6.7.4. Recent Developments
    • 9.6.8. Siemens Healthineers AG
      • 9.6.8.1. Participant's Overview
      • 9.6.8.2. Financial Performance
      • 9.6.8.3. Product Benchmarking
      • 9.6.8.4. Recent Developments
    • 9.6.9. Bio-Rad Laboratories, Inc.
      • 9.6.9.1. Participant's Overview
      • 9.6.9.2. Financial Performance
      • 9.6.9.3. Product Benchmarking
      • 9.6.9.4. Recent Developments
    • 9.6.10. Danaher
      • 9.6.10.1. Participant's Overview
      • 9.6.10.2. Financial Performance
      • 9.6.10.3. Product Benchmarking
      • 9.6.10.4. Recent Developments
    • 9.6.11. OraSure Technologies, Inc.
      • 9.6.11.1. Participant's Overview
      • 9.6.11.2. Financial Performance
      • 9.6.11.3. Product Benchmarking
      • 9.6.11.4. Recent Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제